Casirivimab and Imdevimab Regeneron: An Effective Treatment for COVID19?

Casirivimab and Imdevimab Regeneron: An Effective Treatment for COVID19?

Dec 01, 2021

REGN-COV2™ is a combination therapy that has two products casirivimab and imdevimab. The artificial ‘antibody cocktail’ inhibits the proteins involved in COVID-19 and blocks certain chemicals that can trigger inflammation.

COVID-19 is a disease with no cure, but casirivimab and imdevimab Regeneron can slow down the progress of the COVID-19 by reducing inflammation in various tissue, like mucosa of the respiratory system, the eyes, and the gastrointestinal tract.

It is still unknown if casirivimab can prevent COVID-19 from spreading to other organs.

What is Coronavirus Disease 2019 and Its Effects?

COVID-19 is an infectious respiratory illness caused by a new strain of the SARS-CoV-2 virus.

The virus is passed from person to person via contaminated air droplets produced during coughing or sneezing. Humans can pass the disease on when they touch their hands or surfaces that contain the virus and then touch their eyes, nose, or mouth with those hands.

What are the Symptoms of Coronavirus Disease?

The CDC explains that COVID-19 affects individuals in different ways. The majority of infected people will experience mild to severe illness and recover without going to the hospital.

You may begin to experience the COVID-19 symptoms after five to six days of coming in contact with the virus, although it can take up to 14 days for symptoms to appear.

The most common symptoms are:

  • Fever
  • Cough
  • Tiredness
  • Loss of taste or smell

You may also experience nasal congestion, sore throat, muscle aches, headaches, and diarrhea.

People with pre-existing conditions can experience shortness of breath, chest pain, and loss of mobility and speech. If you experience these symptoms, visit an emergency room near you for immediate treatment.

Why Casirivimab and Imdevimab Regeneron Is the Current Treatment of Choice for COVID- 19

The antiviral casirivimab was developed to treat chronic conditions such as colon cancer, but it was shown that the drug not only stopped the replication of COVID 19 in infected cells but also inhibited other types of influenza viruses from replicating as well. FDA recently approved casirivimab and imdevimab for widespread use in patients between the ages of 18-65.

The REGn-COV2 is administered intravenously. The treatment is most effective when received within 48 hours of first symptoms because viral replication takes place quickly.

REGN-COV2 prevents the further development of proteins required for the assembly of new viral particles. Casirivimab is safe in both adults and children.

The recommended dose for Coronavirus disease is 1200mg, infused as a single intravenous infusion.

Who is Authorized to Use Casirivimab and Imdevimab?

The Regeneron antibody treatment is recommended for adults and adolescents from 12 years who weigh 88 pounds and are at risk of COVID-19. The treatment is also recommended for:

  • Mild to moderate symptoms of COVID-19
  • People not fully vaccinated and are exposed to the COVID-19 virus
  • Patients who are not expected to build up enough immune response because of immunocompromising conditions
  • People exposed to someone with a SARS-Cov-2 virus

What are the Side Effects of Casirivimab and Imdevimab Regeneron?

Since casirivimab and imdevimab are new medications, there is little information about possible side effects. As with all medications, casirivimab and imdevimab could cause unwanted side effects in some patients.

The reported side effects include:

  • Allergic reactions: Allergic reactions can occur throughout and after the REGN-COV2 treatment. If you experience any of the following symptoms of allergic responses, visit an ER near you– a fever, chills, nausea, headaches, shortness of breath, low or high blood pressure, rapid heart rate, or chest pain.
  • Symptoms getting worse after treatment: Fever, difficulty breathing, fast or slow heart rate, tiredness, weakness, or mental confusion are some of the new or worsening symptoms you may experience after the infusion. If these symptoms occur, seek emergency treatment immediately.

REGN-COV2 can cause several adverse effects, some of which are severe and unexpected. Because the drug is still being studied, some dangers haven’t been discovered yet.

It’s conceivable that REGEN-COV will compromise your body’s natural capacity to fight off a future infection of SARS-CoV-2. Similarly, REGN-COV may reduce the immune response of your system to a vaccine for SARS-CoV-2.

There has been no specific research on these potential hazards. It is advisable to seek emergency care if you develop any complications after taking the antibody treatment.

Visit Altus Emergency Center for assistance if any issue arises.

281-628-7300 Check-In Online